Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Launched by CURIS, INC. · Feb 19, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called emavusertib (CA-4948) for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). The trial is divided into two parts: the first part aims to find the best dose of the medication, and the second part will expand on this dosage to see how well it works in specific groups of patients. Eligible participants are adults aged 18 and older who have AML or higher-risk MDS and have already received one or two prior treatments. They should have specific genetic mutations related to their condition, and their overall health must meet certain criteria.

Participants in the trial will take the medication by mouth and will be closely monitored by the medical team. They will need to attend regular appointments for blood tests and may need to undergo bone marrow sampling to check their progress. It’s important for potential participants to know that they will need to follow specific guidelines, such as using effective birth control if applicable, and they should not have certain other health conditions that could complicate their participation. This is a chance to access a new treatment that could help manage their disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males and females ≥18 years of age
• • 2. Life expectancy of at least 3 months
• • 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1
• • 4. Cytomorphology based confirmed diagnosis of MDS or AML (as per World Health Organisation \[WHO\] 2016 classification) with the following characteristics.
• • Phase 1 Dose Escalation (Monotherapy)
• • • AML (primary or secondary, including treatment-related) after failing at least 1 standard treatment (may include chemotherapy, re induction therapy or stem cell transplantation).
• • OR
• • • Higher-risk R/R MDS that are considered resistant/refractory following at least 2 to 3 cycles of hypermethylating agent (HMA) or evidence of early progression
• • Phase 2a Dose Expansion (Monotherapy)
• Patients with:
• • R/R AMLwith FLT3 mutations who have been previously treated with a FLT3 inhibitor
• • R/R AML with spliceosome mutations of SF3B1 or U2AF1
• • R/R hrMDS (IPSS-R score \> 3.5) with spliceosome mutations of SF3B1 or U2AF1
• • Number of pretreatments: 1 or 2
• • 5. Acceptable organ function at screening
• • 6. Ability to swallow and retain oral medications
• • 7. Negative serum pregnancy test in women of childbearing potential
• • 8. Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib
• • 9. Willing and able to provide written informed consent and comply with the requirements of the trial
• • 10. Able to undergo serial bone marrow sampling and peripheral blood sampling
• Exclusion Criteria:
• • 1. Diagnosed with acute promyelocytic leukemia (APL, M3)
• • 2. Has known active central nervous system (CNS) leukemia
• • 3. Allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to start of emavusertib
• • 4. Chronic myeloid leukemia (CML)
• • 5. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib.
• • Localized radiation or surgical resection of skin cancers allowed.
• • 6. Use of any investigational agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib
• • 7. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1within 7 days prior to start of emavusertib; presence of any acute or chronic non-hematological toxicity ≥ Grade 3 at Screening, or prior to start of emavusertib must resolve to ≤ Grade 2.
• • 8. Known allergy or hypersensitivity to any component of the formulation of emavusertib
• • 9. Major surgery, other than diagnostic surgery, \<28 days from the start of emavusertib; minor surgery \<14 days from the start of emavusertib
• • 10. Patients with active advanced malignant solid tumors
• • 11. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness
• • 12. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive or Hepatitis C virus (HCV) infection \<6 months prior to start of emavusertib unless viral load is undetectable, or HCV with cirrhosis
• • 13. Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within 6 months prior to CA-4948, New York Heart Association Class II or greater congestive heart failure, or left ventricular ejection fraction \< 40% by echocardiogram or multi-gated acquisition scan, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, cardiac amyloidosis, congenital long QT syndrome, or QTc with Fridericia's correction (QTcF) that is unmeasurable or \> 450 milliseconds (msec) on Screening electrocardiogram (ECG)
• • 14. Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of emavusertib
• • 15. Pregnant or lactating
• • 16. Systemic fungal, bacterial, viral, or other infection that is not controlled
• • 17. Any other severe, acute, or chronic medical, psychiatric or social condition, or laboratory abnormality that may increase the risk of trial participation or emavusertib administration